[go: up one dir, main page]

WO2007025774A3 - Cysteine protease inhibitors - Google Patents

Cysteine protease inhibitors Download PDF

Info

Publication number
WO2007025774A3
WO2007025774A3 PCT/EP2006/008578 EP2006008578W WO2007025774A3 WO 2007025774 A3 WO2007025774 A3 WO 2007025774A3 EP 2006008578 W EP2006008578 W EP 2006008578W WO 2007025774 A3 WO2007025774 A3 WO 2007025774A3
Authority
WO
WIPO (PCT)
Prior art keywords
protease inhibitors
cysteine protease
compounds
processes
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/008578
Other languages
French (fr)
Other versions
WO2007025774A2 (en
Inventor
Alvaro Isabel Castellote
Lopez Jose Miguel Coteron
Velando Esther Pilar Fernandez
Roman Jose Maria Fiandor
De Francisco Esther Porras
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of WO2007025774A2 publication Critical patent/WO2007025774A2/en
Publication of WO2007025774A3 publication Critical patent/WO2007025774A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Substituted heteroaryl nitrile derivatives of Formula (I), processes for their preparation, pharmaceutical compositions comprising such compounds and use of the compounds as cysteine protease inhibitors are provided.
PCT/EP2006/008578 2005-09-02 2006-08-31 Cysteine protease inhibitors Ceased WO2007025774A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05381043.8 2005-09-02
EP05381043 2005-09-02
EP06110666 2006-03-03
EP06110666.2 2006-03-03

Publications (2)

Publication Number Publication Date
WO2007025774A2 WO2007025774A2 (en) 2007-03-08
WO2007025774A3 true WO2007025774A3 (en) 2007-04-26

Family

ID=37770277

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/EP2006/008578 Ceased WO2007025774A2 (en) 2005-09-02 2006-08-31 Cysteine protease inhibitors
PCT/EP2006/008579 Ceased WO2007025775A2 (en) 2005-09-02 2006-08-31 Cysteine protease inhibitors
PCT/EP2006/008580 Ceased WO2007025776A2 (en) 2005-09-02 2006-08-31 Cysteine protease inhibitors

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/EP2006/008579 Ceased WO2007025775A2 (en) 2005-09-02 2006-08-31 Cysteine protease inhibitors
PCT/EP2006/008580 Ceased WO2007025776A2 (en) 2005-09-02 2006-08-31 Cysteine protease inhibitors

Country Status (4)

Country Link
AR (2) AR055624A1 (en)
PE (2) PE20070332A1 (en)
TW (2) TW200804351A (en)
WO (3) WO2007025774A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2030621A1 (en) * 2007-08-21 2009-03-04 Glaxo Group Limited Novel substituted pyrimidines as cysteine protease inhibitors
EP2077841A1 (en) * 2006-10-30 2009-07-15 Glaxo Group Limited Novel substituted pyrimidines as cysteine protease inhibitors
KR20100023948A (en) 2007-06-08 2010-03-04 닛뽕 케미파 가부시키가이샤 Therapeutic or prophylactic agent for cerebral aneurysm
JPWO2009054454A1 (en) 2007-10-24 2011-03-03 国立大学法人 東京医科歯科大学 Modulator of signal transduction of Toll-like receptor containing cathepsin inhibitor as an active ingredient
DE102008063561A1 (en) * 2008-12-18 2010-08-19 Bayer Cropscience Ag Hydrazides, process for their preparation and their use as herbicides and insecticides
CN102267964B (en) * 2011-06-15 2014-06-18 浙江师范大学 3-hydroxy-2,3-dihydro-benzofuran derivatives as well as synthesis method and application thereof
WO2019190117A1 (en) * 2018-03-28 2019-10-03 한림제약(주) 2-cyanopyrimidin-4-yl carbamate or urea derivative or salt thereof, and pharmaceutical composition including same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040249153A1 (en) * 2001-08-30 2004-12-09 Eva Altmann Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040249153A1 (en) * 2001-08-30 2004-12-09 Eva Altmann Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases

Also Published As

Publication number Publication date
WO2007025775A2 (en) 2007-03-08
WO2007025776A2 (en) 2007-03-08
TW200804352A (en) 2008-01-16
PE20070332A1 (en) 2007-05-11
TW200804351A (en) 2008-01-16
AR055624A1 (en) 2007-08-29
AR057110A1 (en) 2007-11-14
WO2007025776A3 (en) 2007-05-03
WO2007025774A2 (en) 2007-03-08
PE20070612A1 (en) 2007-06-23

Similar Documents

Publication Publication Date Title
WO2008013838A3 (en) Pyridizinone derivatives
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
NO20090295L (en) Substituted heteroaryl derivatives
WO2008005877A3 (en) Inhibitors of c-kit and uses thereof
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2007125103A3 (en) Benzamide glucokinase activators
WO2009156462A3 (en) Organic compounds
WO2009099596A3 (en) Macrocyclic serine protease inhibitors
EA200500203A1 (en) NEW METHOD OF SYNTHESIS AND NEW CRYSTAL FORM OF AGOMELATIN AND PHARMACEUTICAL COMPOSITIONS THAT HERE CONTAINS
WO2007072153A3 (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
WO2009082152A3 (en) Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient
WO2007090749A3 (en) Benzamide and heteroarene derivatives as cetp inhibitors
WO2005005389A3 (en) Malonamide derivatives
WO2009105969A8 (en) Epothilone analogues, their pharmaceutical compositions, their use and their preparations
WO2007030361A3 (en) Benzimidazole thiophene compounds as plk inhibitors
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
WO2007065595A3 (en) Xanthine derivatives, processes for preparing them and their uses
WO2005085236A3 (en) Caspase inhibitors and uses thereof
WO2006110173A3 (en) Novel compounds
IL189286A0 (en) Novel cysteine protease inhibitors and their therapeutic applications
WO2007025776A3 (en) Cysteine protease inhibitors
TW200624429A (en) Novel cysteine protease inhibitors
WO2007068728A3 (en) N-substituted pyrrolopyridinones active as kinase inhibitors
WO2006134499A3 (en) 2-(1h-indolylsulfanyl)-aryl amine derivatives
WO2007087026A3 (en) Solid-state form of amg 706 and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06777150

Country of ref document: EP

Kind code of ref document: A2